Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- The person joining (or their legal representative, if applicable) must be willing and able to give written consent to take part in the trial.
- The person must have measurable disease according to a standard measurement system called RECIST 1.1, including lesions in previously treated areas if those lesions have shown signs of growth.
- A tissue sample from the tumour must be available — either stored from a previous procedure or newly collected — from an area that has not been treated with radiation.
- The person must have a general health and activity level rated 0 or 1 on a standard scale (meaning fully active or able to carry out light work), as assessed by their doctor.
- The person must have adequately functioning major organs such as the liver, kidneys, and blood cells (confirm with trial site for specific thresholds).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are pregnant or breastfeeding.
- People whose cancer has a specific known genetic change that can be targeted by other existing treatments.
- People who have previously received certain types of immunotherapy drugs that work on immune system checkpoints (such as anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or similar treatments).
- People who have previously received any systemic (whole-body) cancer treatment for cancer that has spread to other parts of the body.
- People who have received radiation therapy within 2 weeks before the start of the trial treatment.
- People who have had major surgery within 14 days before joining the trial.
- People who have a condition affecting their immune system, or who are currently taking ongoing steroid medication through the whole body (such as tablets or injections, not creams).
- People who have another cancer that is currently getting worse or has needed active treatment within the past 3 years.
- People with active cancer spread to the brain or the lining around the brain — though people with previously treated or symptom-free brain spread that has been stable on scans may still be considered.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ari Raphael, M.D, Tel-Aviv University school of medicine
Phone: +972-3-6973082
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Objective Response Rate (ORR) per RECIST 1.1 - correlated to TCR repertoire data, such as clonality/diversity.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.